Allogene Therapeutics
ALLO
177 hedge funds and large institutions have $1.28B invested in Allogene Therapeutics in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 68 increasing their positions, 42 reducing their positions, and 29 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 42
38% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 29
13% more call options, than puts
Call options by funds: $2.29M | Put options by funds: $2.02M
5% more funds holding
Funds holding: 169 → 177 (+8)
1.66% less ownership
Funds ownership: 61.87% → 60.21% (-1.7%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
43% less capital invested
Capital invested by funds: $2.26B → $1.28B (-$981M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.4M |
| 2 |
Primecap Management
Pasadena,
California
|
+$18.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$16.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$139M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$55.2M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$34.5M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$19.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$247 | +14 | New |
|
|
LF
202
Lee Financial
Dallas,
Texas
| – | +$247 | +14 | New |
|
|
VCM
203
Versant Capital Management
Phoenix,
Arizona
| – | +$265 | +15 | New |
|
ALLO Hedge Fund Activity: Q4 2021 in Review
177 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2021, worth a combined $1.28B — down 43% from $2.26B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ALLO positions and 29 closed out — a net gain of 11 holders — while 68 added to existing stakes and 42 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $36.4M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $139M sold.
- 177 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2021, up from 169 in Q3 2021.
- Funds reported $1.28B of Allogene Therapeutics stock for Q4 2021, down 43% quarter-over-quarter.
- 40 funds opened new Allogene Therapeutics positions in Q4 2021 and 29 closed out, a net change of +11 holders.
- The largest Allogene Therapeutics buyer in Q4 2021 was Citadel Advisors, an estimated $36.4M added.
- The largest Allogene Therapeutics seller in Q4 2021 was Capital Research Global Investors, an estimated $139M sold.
Based on aggregated 13F filings for Q4 2021.